Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 March 2002

Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers

  • Youn Soo Lee1,
  • Tae Eung Kim,
  • Byung Kee Kim,
  • Yong Gyu Park,
  • Gyu-Moon Kim,
  • Sung-Bae Jee,
  • Ki Sung Ryu,
  • In-Kyung Kim &
  • …
  • Jin Woo Kim 

Experimental & Molecular Medicine volume 34, pages 18–26 (2002)Cite this article

  • 3825 Accesses

  • 24 Citations

  • Metrics details

Abstract

In an effort to understand whether HLA class I and II plays any role in the process of tumorigenesis and metastasis, we have immunohistochemically examined expression of HLA class I and II antigen by using the monoclonal antibodies (mAb) L368 (for β2m of HLA class I), HC-10 (for HLA-B, C heavy chains), and LGII-612.14 (for HLA class II heavy chain) in 5 borderline serous malignancy (BSM), 20 serous adenocarcinomas (SA), 15 borderline mucinous malignancy (BMM), and 10 mucinous adenocarcinomas (MA) of human ovary tumor case tissues. In BSM, the distribution and intensity of HLA expressions failed to reach statistical significance. In SA, HLA class I β2-µglobulin (β2m), HLA-B, C heavy chains and HLA class II heavy chain antigen expressions were down-regulated. Although expressions of HLA-B, C heavy chains and class II heavy chain were down-regulated in metastatic SA, there were no differences in HLA expression levels between primary and metastatic lesions. In BMM, class II heavy chain expressions were down-regulated. In MA, β2m, HLA-B, C heavy chains and class II heavy chain expressions were also down-regulated. Thus, we could distinguish the reduction or absence of HLA molecule expression was related to malignant potential. Loss of HLA class I and II molecules in invasive ovarian cancers raises the possibility that this could be a factor for tumor cells to retain invasiveness.

Similar content being viewed by others

Immunogenetic clustering of 30 cancers

Article Open access 04 May 2022

MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

Article Open access 02 October 2024

HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy

Article 20 January 2021

Article PDF

Author information

Authors and Affiliations

  1. Department of Clinical Pathology, Kangnam St. Mary's Hospital, Korea

    Youn Soo Lee

Authors
  1. Youn Soo Lee
    View author publications

    Search author on:PubMed Google Scholar

  2. Tae Eung Kim
    View author publications

    Search author on:PubMed Google Scholar

  3. Byung Kee Kim
    View author publications

    Search author on:PubMed Google Scholar

  4. Yong Gyu Park
    View author publications

    Search author on:PubMed Google Scholar

  5. Gyu-Moon Kim
    View author publications

    Search author on:PubMed Google Scholar

  6. Sung-Bae Jee
    View author publications

    Search author on:PubMed Google Scholar

  7. Ki Sung Ryu
    View author publications

    Search author on:PubMed Google Scholar

  8. In-Kyung Kim
    View author publications

    Search author on:PubMed Google Scholar

  9. Jin Woo Kim
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Lee, Y., Kim, T., Kim, B. et al. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 34, 18–26 (2002). https://doi.org/10.1038/emm.2002.3

Download citation

  • Published: 01 March 2002

  • Issue date: 01 March 2002

  • DOI: https://doi.org/10.1038/emm.2002.3

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

  • Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment

    • Chin-Jui Wu
    • Ke-Fan Pan
    • Lin-Hung Wei

    Oncogene (2024)

  • Reference Module-Based Analysis of Ovarian Cancer Transcriptome Identifies Important Modules and Potential Drugs

    • Xuedan Lai
    • Peihong Lin
    • Zhou Lin

    Biochemical Genetics (2022)

  • Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses

    • Junko Matsuzaki
    • Takemasa Tsuji
    • Kunle Odunsi

    Scientific Reports (2015)

  • Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer

    • Emilia Andersson
    • Lisa Villabona
    • Giuseppe V. Masucci

    Cancer Immunology, Immunotherapy (2012)

  • Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer

    • Richard P. Ciavarra
    • Roy R. Brown
    • Kenneth D. Somers

    Cancer Immunology, Immunotherapy (2003)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited